Drug Database · Clinicians

Pimecrolimus

Brands (1) ElidelShow all

Calcineurin Inhibitor Immunosuppressant (Calcineurin Inhibitors) US FDA class
Anti-inflammatory PH FDA category

Rx · Prescription drug1 PH product
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 6601e43e-ce7d-446a-8568-8e7b24b86f06, version date April 30, 2026 (Pimecrolimus · Oceanside Pharmaceuticals). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Pimecrolimus Cream, 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Pimecrolimus Cream, 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age [see Warnings and Precautions (5.1), Use in Specific Populations (8.4)].

Pimecrolimus Cream, 1% is a calcineurin inhibitor immunosuppressant indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. (1)

Contraindications

4 CONTRAINDICATIONS Pimecrolimus Cream, 1% is contraindicated in individuals with a history of hypersensitivity to pimecrolimus or any of the components of the cream. Pimecrolimus Cream, 1% is contraindicated in individuals with a history of hypersensitivity to pimecrolimus or any of the components of the cream. (4, 6.2)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

2 DOSAGE AND ADMINISTRATION Apply a thin layer of Pimecrolimus Cream, 1% to the affected skin twice daily. The patient should stop using Pimecrolimus Cream, 1% when signs and symptoms (e.g., itch, rash and redness) resolve and should be instructed on what actions to take if symptoms recur. If signs and symptoms persist beyond 6 weeks, patients should be re-examined by their healthcare provider to confirm the diagnosis of atopic dermatitis.

Continuous long-term use of Pimecrolimus Cream, 1% should be avoided, and application should be limited to areas of involvement with atopic dermatitis [see Warnings and Precautions (5.1)]. The safety of Pimecrolimus Cream, 1% under occlusion, which may promote systemic exposure, has not been evaluated. Avoid use of Pimecrolimus Cream, 1% with occlusive dressings.

  • Apply a thin layer of Pimecrolimus Cream, 1% to the affected skin twice daily. (2)
  • If signs and symptoms persist beyond 6 weeks, patients should be re-examined. (2)
  • Continuous long-term use of Pimecrolimus Cream, 1% should be avoided. (2)
  • Avoid use with occlusive dressings. (2)

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age. The long-term safety and effects of Pimecrolimus Cream, 1% on the developing immune system are unknown. Three Phase 3 pediatric trials were conducted involving 1114 subjects 2-17 years of age. Two trials were 6-week randomized vehicle-controlled trials with a 20-week open-label phase and one was a vehicle-controlled (up to 1 year) safety trial with the option for sequential topical corticosteroid use.

Of these subjects, 542 (49%) were 2-6 years of age. In the short-term trials, 11% of Pimecrolimus subjects did not complete these trials and 1.5% of Pimecrolimus subjects discontinued due to adverse events. In the 1-year trial, 32% of Pimecrolimus subjects did not complete this trial and 3% of Pimecrolimus subjects discontinued due to adverse events.

Most discontinuations were due to unsatisfactory therapeutic effect. The most common local adverse event in the short-term trials of Pimecrolimus Cream, 1% in pediatric subjects ages 2-17 was application site burning (10% vs. 13% vehicle); the incidence in the long-term trial was 9% Pimecrolimus vs. 7% vehicle [see Adverse Reactions (6.1)].

Adverse events that were more frequent (>5%) in subjects treated with Pimecrolimus Cream, 1% compared to vehicle were headache (14% vs. 9%) in the short-term trial. Nasopharyngitis (26% vs. 21%), influenza (13% vs. 4%), pharyngitis (8% vs. 3%), viral infection (7% vs. 1%), pyrexia (13% vs. 5%), cough (16% vs. 11%), and headache (25% vs. 16%) were increased over vehicle in the 1-year safety trial [see Adverse Reactions (6.1)].

In 843 subjects ages 2-17 years treated with Pimecrolimus Cream, 1%, 9 (0.8%) developed eczema herpeticum (5 on Pimecrolimus Cream, 1% alone and 4 on Pimecrolimus Cream, 1% used in sequence with corticosteroids). In 211 subjects on vehicle alone, there were no cases of eczema herpeticum. The majority of adverse events were mild to moderate in severity.

Two Phase 3 trials were conducted involving 436 infants age 3 months-23 months. One 6-week randomized vehicle-controlled trial with a 20-week open-label phase and one safety trial, up to one year, were conducted. In the 6-week trial, 11% of Pimecrolimus and 48% of vehicle subjects did not complete this trial; no subject in either group discontinued due to adverse events.

Infants on Pimecrolimus Cream, 1% had an increased incidence of some adverse events compared to vehicle. In the 6-week vehicle-controlled trial, these adverse events included pyrexia (32% vs. 13% vehicle), URI (24% vs. 14%), nasopharyngitis (15% vs. 8%), gastroenteritis (7% vs. 3%), otitis media (4% vs. 0%), and diarrhea (8% vs. 0%).

In the open-label phase of the trial, for infants who switched to Pimecrolimus Cream, 1% from vehicle, the incidence of the above-cited adverse events approached or equaled the incidence of those subjects who remained on Pimecrolimus Cream, 1%. In the 6-month safety data, 16% of Pimecrolimus and 35% of vehicle subjects discontinued early and 1.5% of Pimecrolimus and 0% of vehicle subjects discontinued due to adverse events.

Infants on Pimecrolimus Cream, 1% had a greater incidence of some adverse events as compared to vehicle. These included pyrexia (30% vs. 20%), URI (21% vs. 17%), cough (15% vs. 9%), hypersensitivity (8% vs. 2%), teething (27% vs. 22%), vomiting (9% vs. 4%), rhinitis (13% vs. 9%), viral rash (4% vs. 0%), rhinorrhea (4% vs. 0%), and wheezing (4% vs. 0%).

The systemic exposure to pimecrolimus from Pimecrolimus Cream, 1% was investigated in 28 pediatric subjects with atopic dermatitis (20%-80% BSA involvement) between the ages of 8 months-14 years. Following twice daily application for 3 weeks, blood concentrations of pimecrolimus were <2 ng/mL with 60% (96/161) of the blood samples having blood concentration below the limit of quantification (0.5 ng/mL).

However, more children (23 children out of the total 28 children investigated) had at least one detectable blood level as compared to the adults (12 adults out of the total 52 adults investigated) over a 3-week treatment period. Due to the erratic nature of the blood levels observed, no correlation could be made between amount of cream, degree of BSA involvement, and blood concentrations.

In general, the blood concentrations measured in adult atopic dermatitis subjects were comparable to those seen in the pediatric population. In a second group of 30 pediatric subjects aged 3-23 months with 10%-92% BSA involvement, following twice daily application for 3 weeks, blood concentrations of pimecrolimus were <2.6 ng/mL with 65% (75/116) of the blood samples having blood concentration below 0.5 ng/mL, and 27% (31/116) below the limit of quantification (0.1 ng/mL) for these trials.

Overall, a higher proportion of detectable blood levels was seen in the pediatric subject population as compared to adult population. This increase in the absolute number of positive blood levels may be due to the larger surface area to body mass ratio seen in these younger subjects. In addition, a higher incidence of upper respiratory symptoms/infections was also seen relative to the older age group in the PK trials.

At this time, a causal relationship between these findings and Pimecrolimus use cannot be ruled out.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Nine (9) subjects ≥65 years old received Pimecrolimus Cream, 1% in Phase 3 trials. Clinical trials of Pimecrolimus Cream, 1% did not include sufficient numbers of subjects aged 65 and over to assess efficacy and safety.

Dosage forms

Philippines

  • Cream: 10 mg/g

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Pimecrolimus as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Pimecrolimus
Package insert
ElidelPimecrolimus
10 mg/g (1%) Cream10 g Aluminum Tube (Box of 1's)
Rx
MEDA ManufacturingFrance
Viatris Pharmaceuticals, Inc.Trader: MEDA Pharma GmbH & Co. KG
DRP-16200
May 25, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Cream, 1%. Each gram of Pimecrolimus Cream, 1% contains 10 mg of pimecrolimus in a whitish cream base. Cream, 1%. (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • • Should not be used in immunocompromised adults and children, including patients on systemic immunosuppressive medications. (5.1)
  • • Avoid treatment on malignant or pre-malignant skin conditions, as these can present as dermatitis. (5.2)
  • • Should not be used in patients with Netherton’s Syndrome or skin diseases with a potential for increased systemic absorption. (5.2)
5.1 Risk of Immunosuppression

5.1 Risk of Immunosuppression Prolonged systemic use of calcineurin inhibitors for sustained immunosuppression in animal studies and transplant patients following systemic administration has been associated with an increased risk of infections, lymphomas, and skin malignancies. These risks are associated with the intensity and duration of immunosuppression.

Based on this information and the mechanism of action, there is a concern about a potential risk with the use of topical calcineurin inhibitors, including Pimecrolimus Cream, 1%. While a causal relationship has not been established, rare cases of skin malignancy and lymphoma have been reported in patients treated with topical calcineurin inhibitors, including Pimecrolimus Cream, 1%.

Therefore:

  • Continuous long-term use of topical calcineurin inhibitors, including Pimecrolimus Cream, 1%, in any age group should be avoided, and application limited to areas of involvement with atopic dermatitis.
  • Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age.
  • Pimecrolimus Cream, 1% should not be used in immunocompromised adults and children, including patients on systemic immunosuppressive medications.
  • If signs and symptoms of atopic dermatitis do not improve within 6 weeks, patients should be re-examined by their healthcare provider and their diagnosis be confirmed.
  • The safety of Pimecrolimus Cream, 1% has not been established beyond 1 year of non-continuous use.
5.2 Application to Malignant or Pre-malignant Skin Conditions

5.2 Application to Malignant or Pre-malignant Skin Conditions The use of Pimecrolimus Cream, 1% should be avoided on malignant or pre-malignant skin conditions. Malignant or pre-malignant skin conditions, such as cutaneous T-cell lymphoma (CTCL), can present as dermatitis. Pimecrolimus Cream, 1% should not be used in patients with Netherton’s Syndrome or other skin diseases where there is the potential for increased systemic absorption of pimecrolimus.

The safety of Pimecrolimus Cream, 1% has not been established in patients with generalized erythroderma. The use of Pimecrolimus Cream, 1% may cause local symptoms such as skin burning (burning sensation, stinging, soreness) or pruritus. Localized symptoms are most common during the first few days of Pimecrolimus Cream, 1% application and typically improve as the lesions of atopic dermatitis resolve [see Adverse Reactions (6.1)].

5.3 Bacterial and Viral Skin Infections

5.3 Bacterial and Viral Skin Infections Before commencing treatment with Pimecrolimus Cream, 1%, bacterial or viral infections at treatment sites should be resolved. Trials have not evaluated the safety and efficacy of Pimecrolimus Cream, 1% in the treatment of clinically infected atopic dermatitis. While patients with atopic dermatitis are predisposed to superficial skin infections including eczema herpeticum (Kaposi’s varicelliform eruption), treatment with Pimecrolimus Cream, 1% may be independently associated with an increased risk of varicella zoster virus infection (chickenpox or shingles), herpes simplex virus infection, or eczema herpeticum.

In clinical trials, 15/1544 (1%) cases of skin papilloma (warts) were observed in subjects using Pimecrolimus Cream, 1%. The youngest subject was age 2 and the oldest was age 12. In cases where there is worsening of skin papillomas or they do not respond to conventional therapy, discontinuation of Pimecrolimus Cream, 1% should be considered until complete resolution of the warts is achieved.

5.4 Patients with Lymphadenopathy

5.4 Patients with Lymphadenopathy In clinical trials, 14/1544 (0.9%) cases of lymphadenopathy were reported while using Pimecrolimus Cream, 1%. These cases of lymphadenopathy were usually related to infections and noted to resolve upon appropriate antibiotic therapy. Of these 14 cases, the majority had either a clear etiology or were known to resolve.

Patients who receive Pimecrolimus Cream, 1% and who develop lymphadenopathy should have the etiology of their lymphadenopathy investigated. In the absence of a clear etiology for the lymphadenopathy, or in the presence of acute infectious mononucleosis, Pimecrolimus Cream, 1% should be discontinued. Patients who develop lymphadenopathy should be monitored to ensure that the lymphadenopathy resolves.

5.5 Sun Exposure

5.5 Sun Exposure During the course of treatment, it is prudent for patients to minimize or avoid natural or artificial sunlight exposure, even while Pimecrolimus Cream, 1% is not on the skin. The potential effects of Pimecrolimus Cream, 1% on skin response to ultraviolet damage are not known.

5.6 Immunocompromised Patients

5.6 Immunocompromised Patients The safety and efficacy of Pimecrolimus Cream, 1% in immunocompromised patients have not been studied.

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Potential interactions between Pimecrolimus Cream, 1% and other drugs, including immunizations, have not been systematically evaluated. Due to low blood levels of pimecrolimus detected in some patients after topical application, systemic drug interactions are not expected, but cannot be ruled out. The concomitant administration of known CYP3A family of inhibitors in patients with widespread and/or erythrodermic disease should be done with caution. Some examples of such drugs are erythromycin, itraconazole, ketoconazole, fluconazole, calcium channel blockers and cimetidine.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Studies with human liver microsomes indicate that pimecrolimus is metabolized in vitro by the CYP3A subfamily of metabolizing enzymes.

The concomitant administration of known CYP3A family of inhibitors in patients with widespread and/or erythrodermic disease should be done with caution.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The most commonly reported adverse reactions (≥1%) were application site burning, headache, nasopharyngitis, cough, influenza, pyrexia and viral infection. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. No phototoxicity and no photoallergenicity were detected in clinical trials with 24 and 33 normal volunteers, respectively.

In human dermal safety trials, Pimecrolimus Cream, 1% did not induce contact sensitization or cumulative irritation. In a 1-year safety trial in pediatric subjects age 2-17 years old involving sequential use of Pimecrolimus Cream, 1% and a topical corticosteroid, 43% of Pimecrolimus Cream, 1% treated subjects and 68% of vehicle-treated subjects used corticosteroids during the trial.

Corticosteroids were used for more than 7 days by 34% of Pimecrolimus Cream, 1% treated subjects and 54% of vehicle-treated subjects. An increased incidence of impetigo, skin infection, superinfection (infected atopic dermatitis), rhinitis, and urticaria were found in the subjects that had used Pimecrolimus Cream, 1% and topical corticosteroid sequentially as compared to Pimecrolimus Cream, 1% alone.

In three randomized, double-blind vehicle-controlled pediatric trials and one active-controlled adult trial, 843 and 328 subjects, respectively, were treated with Pimecrolimus Cream, 1%. In these clinical trials, 48 (4%) of the 1171 Pimecrolimus Cream, 1% treated subjects and 13 (3%) of 408 vehicle-treated subjects discontinued therapy due to adverse events.

Discontinuations for AEs were primarily due to application site reactions and cutaneous infections. The most common application site reaction was application site burning, which occurred in 8%-26% of subjects treated with Pimecrolimus Cream, 1%. Table 1 depicts the incidence of adverse events pooled across the two identically designed 6-week trials with their open label extensions and the 1-year safety trial for pediatric subjects ages 2-17.

Data from the adult active-controlled trial are also included in Table 1. Adverse events are listed regardless of relationship to trial drug. Table 1. Treatment Emergent Adverse Events (≥1%) in Pimecrolimus Cream, 1% Treatment Groups Pediatric Subjects Ages 2-17 years Vehicle-Controlled (6 weeks) Pediatric Subjects Open-Label Pediatric Subjects Vehicle-Controlled (1 year) Adult Active Comparator (1 year) (20 weeks) Pimecrolimus Cream, 1% Vehicle Pimecrolimus Cream, 1% Pimecrolimus Cream, 1% Vehicle Pimecrolimus Cream, 1% (N=267) N (%) (N=136) N (%) (N=335) N (%) (N=272) N (%) (N=75) N (%) (N=328) N (%) At least 1 AE 182 (68.2%) 97 (71.3%) 240 (72.0%) 230 (84.6%) 56 (74.7%) 256 (78.0%) Infections and Infestations Upper Respiratory Tract Infection NOS 38 (14.2%) 18 (13.2%) 65 (19.4%) 13 (4.8%) 6 (8.0%) 14 (4.3%) Nasopharyngitis 27 (10.1%) 10 (7.4%) 32 (19.6%) 72 (26.5%) 16 (21.3%) 25 (7.6%) Skin Infection NOS 8 (3.0%) 9 (5.1%) 18 (5.4%) 6 (2.2%) 3 (4.0%) 21 (6.4%) Influenza 8 (3.0%) 1 (0.7%) 22 (6.6%) 36 (13.2%) 3 (4.0%) 32 (9.8%) Ear Infection NOS 6 (2.2%) 2 (1.5%) 19 (5.7%) 9 (3.3%) 1 (1.3%) 2 (0.6%) Otitis Media 6 (2.2%) 1 (0.7%) 10 (3.0%) 8 (2.9%) 4 (5.3%) 2 (0.6%) Impetigo 5 (1.9%) 3 (2.2%) 12 (3.6%) 11 (4.0%) 4 (5.3%) 8 (2.4%) Bacterial Infection 4 (1.5%) 3 (2.2%) 4 (1.2%) 3 (1.1%) 0 6 (1.8%) Folliculitis 3 (1.1%) 1 (0.7%) 3 (0.9%) 6 (2.2%) 3 (4.0%) 20 (6.1%) Sinusitis 3 (1.1%) 1 (0.7%) 11 (3.3%) 6 (2.2%) 1 (1.3%) 2 (0.6%) Pneumonia NOS 3 (1.1%) 1 (0.7%) 5 (1.5%) 0 1 (1.3%) 1 (0.3%) Pharyngitis NOS 2 (0.7%) 2 (1.5%) 3 (0.9%) 22 (8.1%) 2 (2.7%) 3 (0.9%) Pharyngitis Streptococcal 2 (0.7%) 2 (1.5%) 10 (3.0%) 0 <1% 0 Molluscum Contagiosum 2 (0.7%) 0 4 (1.2%) 5 (1.8%) 0 0 Staphylococcal Infection 1 (0.4%) 5 (3.7%) 7 (2.1%) 0 <1% 3 (0.9%) Bronchitis NOS 1 (0.4%) 3 (2.2%) 4 (1.2%) 29 (10.7%) 6 (8.0%) 8 (2.4%) Herpes Simplex 1 (0.4%) 0 4 (1.2%) 9 (3.3%) 2 (2.7%) 13 (4.0%) Tonsillitis NOS 1 (0.4%) 0 3 (0.9%) 17 (6.3%) 0 2 (0.6%) Viral Infection NOS 2 (0.7%) 1 (0.7%) 1 (0.3%) 18 (6.6%) 1 (1.3%) 0 Gastroenteritis NOS 0 3 (2.2%) 2 (0.6%) 20 (7.4%) 2 (2.7%) 6 (1.8%) Chickenpox 2 (0.7%) 0 3 (0.9%) 8 (2.9%) 3 (4.0%) 1 (0.3%) Skin Papilloma 1 (0.4%) 0 2 (0.6%) 9 (3.3%) <1% 0 Tonsillitis Acute NOS 0 0 0 7 (2.6%) 0 0 Upper Respiratory Tract Infection Viral NOS 1 (0.4%) 0 3 (0.9%) 4 (1.5%) 0 1 (0.3%) Herpes Simplex Dermatitis 0 0 1 (0.3%) 4 (1.5%) 0 2 (0.6%) Bronchitis Acute NOS 0 0 0 4 (1.5%) 0 0 Eye Infection NOS 0 0 0 3 (1.1%) <1% 1 (0.3%) General Disorders and Administration Site Conditions Application Site Burning 28 (10.4%) 17 (12.5%) 5 (1.5%) 23 (8.5%) 5 (6.7%) 85 (25.9%) Pyrexia 20 (7.5%) 12 (8.8%) 41 (12.2%) 34 (12.5%) 4 (5.3%) 4 (1.2%) Application Site Reaction NOS 8 (3.0%) 7 (5.1%) 7 (2.1%) 9 (3.3%) 2 (2.7%) 48 (14.6%) Application Site Irritation 8 (3.0%) 8 (5.9%) 3 (0.9%) 1 (0.4%) 3 (4.0%) 21 (6.4%) Influenza-Like Illness 1 (0.4%) 0 2 (0.6%) 5 (1.8%) 2 (2.7%) 6 (1.8%) Application Site Erythema 1 (0.4%) 0 0 6 (2.2%) 0 7 (2.1%) Application Site Pruritus 3 (1.1%) 2 (1.5%) 2 (0.6%) 5 (1.8%) 0 18 (5.5%) Respiratory, Thoracic and Mediastinal Disorders Cough 31 (11.6%) 11 (8.1%) 31 (9.3%) 43 (15.8%) 8 (10.7%) 8 (2.4%) Nasal Congestion 7 (2.6%) 2 (1.5%) 6 (1.8%) 4 (1.5%) 1 (1.3%) 2 (0.6%) Rhinorrhea 5 (1.9%) 1 (0.7%) 3 (0.9%) 1 (0.4%) 1 (1.3%) 0 Asthma Aggravated 4 (1.5%) 3 (2.2%) 13 (3.9%) 3 (1.1%) 1 (1.3%) 0 Sinus Congestion 3 (1.1%) 1 (0.7%) 2 (0.6%) <1% <1% 3 (0.9%) Rhinitis 1 (0.4%) 0 5 (1.5%) 12 (4.4%) 5 (6.7%) 7 (2.1%) Wheezing 1 (0.4%) 1 (0.7%) 4 (1.2%) 2 (0.7%) <1% 0 Asthma NOS 2 (0.7%) 1 (0.7%) 11 (3.3%) 10 (3.7%) 2 (2.7%) 8 (2.4%) Epistaxis 0 1 (0.7%) 0 9 (3.3%) 1 (1.3%) 1 (0.3%) Dyspnea NOS 0 0 0 5 (1.8%) 1 (1.3%) 2 (0.6%) Gastrointestinal Disorders Abdominal Pain Upper 11 (4.1%) 6 (4.4%) 10 (3.0%) 15 (5.5%) 5 (6.7%) 1 (0.3%) Sore Throat 9 (3.4%) 5 (3.7%) 15 (5.4%) 22 (8.1%) 4 (5.3%) 12 (3.7%) Vomiting NOS 8 (3.0%) 6 (4.4%) 14 (4.2%) 18 (6.6%) 6 (8.0%) 2 (0.6%) Diarrhea NOS 3 (1.1%) 1 (0.7%) 2 (0.6%) 21 (7.7%) 4 (5.3%) 7 (2.1%) Nausea 1 (0.4%) 3 (2.2%) 4 (1.2%) 11 (4.0%) 5 (6.7%) 6 (1.8%) Abdominal Pain NOS 1 (0.4%) 1 (0.7%) 5 (1.5%) 12 (4.4%) 3 (4.0%) 1 (0.3%) Toothache 1 (0.4%) 1 (0.7%) 2 (0.6%) 7 (2.6%) 1 (1.3%) 2 (0.6%) Constipation 1 (0.4%) 0 2 (0.6%) 10 (3.7%) <1% 0 Loose Stools 0 1 (0.7%) 4 (1.2%) <1% <1% 0 Reproductive System and Breast Disorders Dysmenorrhea 3 (1.1%) 0 5 (1.5%) 3 (1.1%) 1 (1.3%) 4 (1.2%) Eye Disorders Conjunctivitis NEC 2 (0.7%) 1 (0.7%) 7 (2.1%) 6 (2.2%) 3 (4.0%) 10 (3.0%) Skin and Subcutaneous Tissue Disorders Urticaria 3 (1.1%) 0 1 (0.3%) 1 (0.4%) <1% 3 (0.9%) Acne NOS 0 1 (0.7%) 1 (0.3%) 4 (1.5%) <1% 6 (1.8%) Immune System Disorders Hypersensitivity NOS 11 (4.1%) 6 (4.4%) 16 (4.8%) 14 (5.1%) 1 (1.3%) 11 (3.4%) Injury and Poisoning Accident NOS 3 (1.1%) 1 (0.7%) 1 (0.3%) <1% 1 (1.3%) 0 Laceration 2 (0.7%) 1 (0.7%) 5 (1.5%) <1% <1% 0 Musculoskeletal, Connective Tissue and Bone Disorders Back Pain 1 (0.4%) 2 (1.5%) 1 (0.3%) <1% 0 6 (1.8%) Arthralgias 0 0 1 (0.3%) 3 (1.1%) 1 (1.3%) 5 (1.5%) Ear and Labyrinth Disorders Earache 2 (0.7%) 1 (0.7%) 0 8 (2.9%) 2 (2.7%) 0 Nervous System Disorders Headache 37 (13.9%) 12 (8.8%) 38 (11.3%) 69 (25.4%) 12 (16.0%) 23 (7.0%) Two cases of septic arthritis have been reported in infants less than one year of age in clinical trials conducted with Pimecrolimus Cream, 1% (n = 2443).

Causality has not been established.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of Pimecrolimus Cream, 1%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

General: Anaphylactic reactions, ocular irritation after application of the cream to the eye lids or near the eyes, angioneurotic edema, facial edema, skin flushing associated with alcohol use, skin discoloration. Hematology/Oncology: Lymphomas, basal cell carcinoma, malignant melanoma, squamous cell carcinoma.

Adverse reaction frequency tables (US label) US FDA label
Table 1. Treatment Emergent Adverse Events (≥1%) in Pimecrolimus Cream, 1% Treatment Groups
Pediatric SubjectsAges 2-17 years Vehicle-Controlled (6 weeks)Pediatric Subjects Open-LabelPediatric Subjects Vehicle-Controlled (1 year)Adult Active Comparator (1 year)
(20 weeks)
Pimecrolimus Cream, 1% VehiclePimecrolimus Cream, 1%Pimecrolimus Cream, 1% VehiclePimecrolimus Cream, 1%
(N=267) N (%)(N=136) N (%)(N=335) N (%)(N=272) N (%)(N=75) N (%)(N=328) N (%)
At least 1 AE182 (68.2%)97 (71.3%)240 (72.0%)230 (84.6%)56 (74.7%)256 (78.0%)
Infections and Infestations
Upper Respiratory Tract Infection NOS38 (14.2%)18 (13.2%)65 (19.4%)13 (4.8%)6 (8.0%)14 (4.3%)
Nasopharyngitis27 (10.1%)10 (7.4%)32 (19.6%)72 (26.5%)16 (21.3%)25 (7.6%)
Skin Infection NOS8 (3.0%)9 (5.1%)18 (5.4%)6 (2.2%)3 (4.0%)21 (6.4%)
Influenza8 (3.0%)1 (0.7%)22 (6.6%)36 (13.2%)3 (4.0%)32 (9.8%)
Ear Infection NOS6 (2.2%)2 (1.5%)19 (5.7%)9 (3.3%)1 (1.3%)2 (0.6%)
Otitis Media6 (2.2%)1 (0.7%)10 (3.0%)8 (2.9%)4 (5.3%)2 (0.6%)
Impetigo5 (1.9%)3 (2.2%)12 (3.6%)11 (4.0%)4 (5.3%)8 (2.4%)
Bacterial Infection4 (1.5%)3 (2.2%)4 (1.2%)3 (1.1%)06 (1.8%)
Folliculitis3 (1.1%)1 (0.7%)3 (0.9%)6 (2.2%)3 (4.0%)20 (6.1%)
Sinusitis3 (1.1%)1 (0.7%)11 (3.3%)6 (2.2%)1 (1.3%)2 (0.6%)
Pneumonia NOS3 (1.1%)1 (0.7%)5 (1.5%)01 (1.3%)1 (0.3%)
Pharyngitis NOS2 (0.7%)2 (1.5%)3 (0.9%)22 (8.1%)2 (2.7%)3 (0.9%)
Pharyngitis Streptococcal2 (0.7%)2 (1.5%)10 (3.0%)0<1%0
Molluscum Contagiosum2 (0.7%)04 (1.2%)5 (1.8%)00
Staphylococcal Infection1 (0.4%)5 (3.7%)7 (2.1%)0<1%3 (0.9%)
Bronchitis NOS1 (0.4%)3 (2.2%)4 (1.2%)29 (10.7%)6 (8.0%)8 (2.4%)
Herpes Simplex1 (0.4%)04 (1.2%)9 (3.3%)2 (2.7%)13 (4.0%)
Tonsillitis NOS1 (0.4%)03 (0.9%)17 (6.3%)02 (0.6%)
Viral Infection NOS2 (0.7%)1 (0.7%)1 (0.3%)18 (6.6%)1 (1.3%)0
Gastroenteritis NOS03 (2.2%)2 (0.6%)20 (7.4%)2 (2.7%)6 (1.8%)
Chickenpox2 (0.7%)03 (0.9%)8 (2.9%)3 (4.0%)1 (0.3%)
Skin Papilloma1 (0.4%)02 (0.6%)9 (3.3%)<1%0
Tonsillitis Acute NOS0007 (2.6%)00
Upper Respiratory Tract Infection Viral NOS1 (0.4%)03 (0.9%)4 (1.5%)01 (0.3%)
Herpes Simplex Dermatitis001 (0.3%)4 (1.5%)02 (0.6%)
Bronchitis Acute NOS0004 (1.5%)00
Eye Infection NOS0003 (1.1%)<1%1 (0.3%)
General Disorders and Administration Site Conditions
Application Site Burning28 (10.4%)17 (12.5%)5 (1.5%)23 (8.5%)5 (6.7%)85 (25.9%)
Pyrexia20 (7.5%)12 (8.8%)41 (12.2%)34 (12.5%)4 (5.3%)4 (1.2%)
Application Site Reaction NOS8 (3.0%)7 (5.1%)7 (2.1%)9 (3.3%)2 (2.7%)48 (14.6%)
Application Site Irritation8 (3.0%)8 (5.9%)3 (0.9%)1 (0.4%)3 (4.0%)21 (6.4%)
Influenza-Like Illness1 (0.4%)02 (0.6%)5 (1.8%)2 (2.7%)6 (1.8%)
Application Site Erythema1 (0.4%)006 (2.2%)07 (2.1%)
Application Site Pruritus3 (1.1%)2 (1.5%)2 (0.6%)5 (1.8%)018 (5.5%)
Respiratory, Thoracic and Mediastinal Disorders
Cough31 (11.6%)11 (8.1%)31 (9.3%)43 (15.8%)8 (10.7%)8 (2.4%)
Nasal Congestion7 (2.6%)2 (1.5%)6 (1.8%)4 (1.5%)1 (1.3%)2 (0.6%)
Rhinorrhea5 (1.9%)1 (0.7%)3 (0.9%)1 (0.4%)1 (1.3%)0
Asthma Aggravated4 (1.5%)3 (2.2%)13 (3.9%)3 (1.1%)1 (1.3%)0
Sinus Congestion3 (1.1%)1 (0.7%)2 (0.6%)<1%<1%3 (0.9%)
Rhinitis1 (0.4%)05 (1.5%)12 (4.4%)5 (6.7%)7 (2.1%)
Wheezing1 (0.4%)1 (0.7%)4 (1.2%)2 (0.7%)<1%0
Asthma NOS2 (0.7%)1 (0.7%)11 (3.3%)10 (3.7%)2 (2.7%)8 (2.4%)
Epistaxis01 (0.7%)09 (3.3%)1 (1.3%)1 (0.3%)
Dyspnea NOS0005 (1.8%)1 (1.3%)2 (0.6%)
Gastrointestinal Disorders
Abdominal Pain Upper11 (4.1%)6 (4.4%)10 (3.0%)15 (5.5%)5 (6.7%)1 (0.3%)
Sore Throat9 (3.4%)5 (3.7%)15 (5.4%)22 (8.1%)4 (5.3%)12 (3.7%)
Vomiting NOS8 (3.0%)6 (4.4%)14 (4.2%)18 (6.6%)6 (8.0%)2 (0.6%)
Diarrhea NOS3 (1.1%)1 (0.7%)2 (0.6%)21 (7.7%)4 (5.3%)7 (2.1%)
Nausea1 (0.4%)3 (2.2%)4 (1.2%)11 (4.0%)5 (6.7%)6 (1.8%)
Abdominal Pain NOS1 (0.4%)1 (0.7%)5 (1.5%)12 (4.4%)3 (4.0%)1 (0.3%)
Toothache1 (0.4%)1 (0.7%)2 (0.6%)7 (2.6%)1 (1.3%)2 (0.6%)
Constipation1 (0.4%)02 (0.6%)10 (3.7%)<1%0
Loose Stools01 (0.7%)4 (1.2%)<1%<1%0
Reproductive System and Breast Disorders
Dysmenorrhea3 (1.1%)05 (1.5%)3 (1.1%)1 (1.3%)4 (1.2%)
Eye Disorders
Conjunctivitis NEC2 (0.7%)1 (0.7%)7 (2.1%)6 (2.2%)3 (4.0%)10 (3.0%)
Skin and Subcutaneous Tissue Disorders
Urticaria3 (1.1%)01 (0.3%)1 (0.4%)<1%3 (0.9%)
Acne NOS01 (0.7%)1 (0.3%)4 (1.5%)<1%6 (1.8%)
Immune System Disorders
Hypersensitivity NOS11 (4.1%)6 (4.4%) 16 (4.8%)14 (5.1%)1 (1.3%)11 (3.4%)
Injury and Poisoning
Accident NOS3 (1.1%)1 (0.7%)1 (0.3%)<1%1 (1.3%)0
Laceration2 (0.7%)1 (0.7%)5 (1.5%)<1%<1%0
Musculoskeletal, Connective Tissue and Bone Disorders
Back Pain1 (0.4%)2 (1.5%)1 (0.3%)<1%06 (1.8%)
Arthralgias001 (0.3%)3 (1.1%)1 (1.3%)5 (1.5%)
Ear and Labyrinth Disorders
Earache2 (0.7%)1 (0.7%)08 (2.9%)2 (2.7%)0
Nervous System Disorders
Headache37 (13.9%)12 (8.8%)38 (11.3%)69 (25.4%)12 (16.0%)23 (7.0%)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Pregnancy Category C There are no adequate and well-controlled studies with Pimecrolimus Cream, 1% in pregnant women. Therefore, Pimecrolimus Cream, 1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In dermal embryofetal developmental studies, no maternal or fetal toxicity was observed up to the highest practicable doses tested, 10 mg/kg/day (1% pimecrolimus cream) in rats (0.14X MRHD based on body surface area) and 10 mg/kg/day (1% pimecrolimus cream) in rabbits (0.65X MRHD based on AUC comparisons).

The 1% pimecrolimus cream was administered topically for 6 hours/day during the period of organogenesis in rats and rabbits (gestational days 6-21 in rats and gestational days 6-20 in rabbits). A second dermal embryofetal development study was conducted in rats using pimecrolimus cream applied dermally to pregnant rats (1 g cream/kg body weight of 0.2%, 0.6% and 1.0% pimecrolimus cream) from gestation day 6 to 17 at doses of 2, 6, and 10 mg/kg/day with daily exposure of approximately 22 hours.

No maternal, reproductive, or embryofetal toxicity attributable to pimecrolimus was noted at 10 mg/kg/day (0.66X MRHD based on AUC comparisons), the highest dose evaluated in this study. No teratogenicity was noted in this study at any dose. A combined oral fertility and embryofetal developmental study was conducted in rats and an oral embryofetal developmental study was conducted in rabbits.

Pimecrolimus was administered during the period of organogenesis (2 weeks prior to mating until gestational day 16 in rats, gestational days 6-18 in rabbits) up to dose levels of 45 mg/kg/day in rats and 20 mg/kg/day in rabbits. In the absence of maternal toxicity, indicators of embryofetal toxicity (post-implantation loss and reduction in litter size) were noted at 45 mg/kg/day (38X MRHD based on AUC comparisons) in the oral fertility and embryofetal developmental study conducted in rats.

No malformations in the fetuses were noted at 45 mg/kg/day (38X MRHD based on AUC comparisons) in this study. No maternal toxicity, embryotoxicity or teratogenicity were noted in the oral rabbit embryofetal developmental toxicity study at 20 mg/kg/day (3.9X MRHD based on AUC comparisons), which was the highest dose tested in this study.

A second oral embryofetal development study was conducted in rats. Pimecrolimus was administered during the period of organogenesis (gestational days 6 – 17) at doses of 2, 10 and 45 mg/kg/day. Maternal toxicity, embryolethality and fetotoxicity were noted at 45 mg/kg/day (271X MRHD based on AUC comparisons). A slight increase in skeletal variations that were indicative of delayed skeletal ossification was also noted at this dose.

No maternal toxicity, embryolethality or fetotoxicity were noted at 10 mg/kg/day (16X MRHD based on AUC comparisons). No teratogenicity was noted in this study at any dose. A second oral embryofetal development study was conducted in rabbits. Pimecrolimus was administered during the period of organogenesis (gestational days 7 – 20) at doses of 2, 6 and 20 mg/kg/day.

Maternal toxicity, embryotoxicity and fetotoxicity were noted at 20 mg/kg/day (12X MRHD based on AUC comparisons). A slight increase in skeletal variations that were indicative of delayed skeletal ossification was also noted at this dose. No maternal toxicity, embryotoxicity or fetotoxicity were noted at 6 mg/kg/day (5X MRHD based on AUC comparisons).

No teratogenicity was noted in this study at any dose. An oral peri- and postnatal developmental study was conducted in rats. Pimecrolimus was administered from gestational day 6 through lactational day 21 up to a dose level of 40 mg/kg/day. Only 2 of 22 females delivered live pups at the highest dose of 40 mg/kg/day. Postnatal survival, development of the F1 generation, their subsequent maturation and fertility were not affected at 10 mg/kg/day (12X MRHD based on AUC comparisons), the highest dose evaluated in this study.

Pimecrolimus was transferred across the placenta in oral rat and rabbit embryofetal developmental studies.

Breastfeeding considerations

Lactation (US label) US FDA label

8.3 Nursing Mothers It is not known whether this drug is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from pimecrolimus, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Mechanism of action

12.1 Mechanism of Action The mechanism of action of pimecrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that pimecrolimus binds with high affinity to macrophilin-12 (FKBP-12) and inhibits the calcium-dependent phosphatase, calcineurin.

As a consequence, it inhibits T-cell activation by blocking the transcription of early cytokines. In particular, pimecrolimus inhibits at nanomolar concentrations Interleukin-2 and interferon gamma (Th1-type) and Interleukin-4 and Interleukin-10 (Th2-type) cytokine synthesis in human T-cells. In addition, pimecrolimus prevents the release of inflammatory cytokines and mediators from mast cells in vitro after stimulation by antigen/IgE.

US FDA label

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption In adult subjects (n=52) being treated for atopic dermatitis [13%-62% Body Surface Area (BSA) involvement] for periods up to a year, a maximum pimecrolimus concentration of 1.4 ng/mL was observed among those subjects with detectable blood levels. In the majority of samples in adult (91%; 1244/1362) subjects, blood concentrations of pimecrolimus were below 0.5 ng/mL.

Data on blood levels of pimecrolimus measured in pediatric subjects are described in Use in Specific Populations (8.4). Distribution Laboratory in vitro plasma protein binding studies using equilibrium gel filtration have shown that 99.5% of pimecrolimus in plasma is bound to proteins over the pimecrolimus concentration range of 2-100 ng/mL tested.

The major fraction of pimecrolimus in plasma appears to be bound to various lipoproteins. As with other topical calcineurin inhibitors, it is not known whether pimecrolimus is absorbed into cutaneous lymphatic vessels or in regional lymph nodes. Metabolism Following the administration of a single oral radiolabeled dose of pimecrolimus, numerous circulating O-demethylation metabolites were seen.

Studies with human liver microsomes indicate that pimecrolimus is metabolized in vitro by the CYP3A subfamily of metabolizing enzymes. No evidence of skin mediated drug metabolism was identified in vivo using the minipig or in vitro using stripped human skin. Elimination Based on the results of the aforementioned radiolabeled study, following a single oral dose of pimecrolimus, ~81% of the administered radioactivity was recovered, primarily in the feces (78.4%) as metabolites.

Less than 1% of the radioactivity found in the feces was due to unchanged pimecrolimus.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Pimecrolimus · Oceanside Pharmaceuticals [US FDA-approved label, version 4, April 30, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6601e43e-ce7d-446a-8568-8e7b24b86f06
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .